Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
Trump says Iran war deal close as Strait of Hormuz tensions linger
Fire breaks out at New Zealand's Wellington airport, disrupting flights
Ukraine and Russia trade overnight drone strikes, officials say
UN says Taliban arrest 30 women for violating hijab rules in Afghanistan
Trump cancels US strikes on Iran, citing progress in talks
South Korea court sentences ex-President Yoon to 30-year jail term in drone case
Thai king's eldest daughter dies, aged 47, after long illness
US confirms third strike on Indian-crewed tankers this week
